Integra Lifesciences Holdings IART
Integra LifeSciences raises $450M in notes
Item 1.01 Enters material agreement, Item 1.02 Ends material agreement, Item 2.03 Takes on debt
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001193125-26-425271
- $450M in 9.500% Senior Secured Notes due 2033
- Credit Agreement includes $1.65B in facilities
- Interest rates vary based on leverage ratio
- Notes are secured and guaranteed by subsidiaries
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- In an 8-K filed October 19, 2026, Integra LifeSciences Holdings Corporation reported entering an amended and restated credit agreement with a syndicate of lending banks, with Bank of America, N.A. as Administrative Agent.
- The same day it completed a private unregistered offering of $450 million aggregate principal amount of its 9.500% Senior Secured Notes due 2033.
- The obligations are guaranteed by substantially all wholly-owned domestic subsidiaries and secured on a first-priority basis.
- The applicable rate for Term SOFR borrowings under the Term Loan B Facility is 4.25%.
- For the Revolving Facility and Term Loan A Facility it is initially 3.00%, and after the compliance certificate for the quarter ending December 31, 2026 it will range from 2.00% to 3.25%.
- The commitment fee is fixed at 0.30% until then.
- The Notes bear interest at 9.500% per year, payable on May 1 and November 1, starting May 1, 2027, and mature on November 1, 2033.
- They are senior secured obligations, ranking pari passu with indebtedness under the Credit Agreement as to the collateral owned by the Company.
- Under Item 1.02, the Company used part of the proceeds to repay in full the term loans and revolving loans under its Seventh Amended and Restated Credit Agreement dated March 24, 2023, and the revolving commitments were terminated.
- That agreement had provided a $1.3 billion revolving facility and a $775 million term loan facility.
- The Company reported no early termination penalties.
- Item 2.03 incorporates Item 1.01 by reference.
12 of 12 claims matched the filing text.
For perspective, checked against its own source
From the 10-Q for the quarter ended September 30, 2026
- In its 10-Q for the quarter ended September 30, 2026, the Company reported revenue of $411.2 million, net income of $14.9 million, and revenue growth of +2.3% from a year earlier.
From the filing
Item 1.01
Item 1.01
Entry Into a Material Definitive Agreement
On October 19, 2026, Integra LifeSciences Holdings Corporation (the "Company") entered into an amended and restated credit agreement with a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and a L/C Issuer1 (the "Credit Agreement"). In addition, on October 19, 2026 the Company completed a private unregistered offering of $450 million aggregate principal amount of its 9.500% Senior Secured Notes due 20332 (the "Notes").
Credit Agreement
The Credit Agreement makes an aggregate principal amount of up to $1.65 billion available to the Company through the following facilities: (i) a $600 million senior secured revolving credit facility with a five year maturity (the "Revolving Facility"), subject to certain sublimits for the issuance of letters of credit and swing line loans, (ii) a $600 million senior secured term loan A facility with a five year maturity (the "Term Loan A Facility") and (iii) a $450 million senior secured term loan B facility with a seven year maturity (the "Term Loan B Facility"). The Company's obligations under the Credit Agreement are guaranteed by substantially all of its existing and future wholly-owned domestic subsidiaries, subject to customary exceptions, and are secured on a first-priority basis3 by substantially all of the tangible and intangible assets of the Company and the guarantors, subject to customary exceptions (including real property and leasehold interests).
Borrowings under the Credit Agreement bear interest, at the Company's option, at a rate equal to (i) Term SOFR (as defined in the Credit Agreement) in effect from time to time plus the applicable rate or (ii) the highest of (w) the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus one half of 1.00%, (x) the prime lending rate of Bank of America, N.A. or (y) the one-month Term SOFR plus 1.00% and (z) 1.00%. The applicable rate for Term SOFR borrowings under the Term Loan B Facility is 4.25%.4 The applicable rate for Term SOFR borrowings under the Revolving Facility and the Term Loan A Facility is initially 3.00% and, following delivery of the compliance certificate for the fiscal quarter ending December 31, 2026, will range from 2.00% to 3.25%5 based on the Company's consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date to (b) consolidated EBITDA for the period of four consecutive fiscal quarters ending on such date) at the time of the applicable borrowing.
The Company will also pay an annual commitment fee of 0.20% to 0.35% (fixed at 0.30% until delivery of the compliance certificate for the fiscal quarter ending December 31, 20266) on the daily amount by which the commitments under the Revolving Facility exceed the outstanding loans and letters of credit under the Revolving Facility.
The foregoing description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Credit Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.
In addition, on October 19, 2026, the Company and the subsidiary guarantors of the Company entered into a ratification agreement to the Credit Agreement with Bank of America, N.A., as Administrative Agent (the "Ratification Agreement"). A copy of the Ratification Agreement is filed as Exhibit 10.2 hereto and is incorporated herein by reference.
Indenture
On October 19, 2026, the Company entered into an Indenture (the "Indenture"), dated as of October 19, 2026, with Truist Bank, as trustee and notes collateral agent (the "Trustee") and the guarantor parties thereto (the "Guarantors"), relating to the issuance of the Notes.
The Notes bear interest at a rate of 9.500% per year, payable semi-annually in arrears on May 1 and November 1 of each year, commencing May 1, 2027.7 7The Notes will mature on November 1, 20337, unless earlier repurchased or redeemed.
The Notes will be guaranteed on a senior secured basis, jointly and severally, by each of the Company's wholly-owned domestic subsidiaries that is a guarantor under our Credit Agreement and, subject to certain exceptions, each of the Company's current and future wholly-owned domestic subsidiaries that guarantees indebtedness under any of the Company or any guarantor's credit facilities or capital markets debt with an aggregate outstanding principal amount in excess of $200 million.
The Notes will be the Company's senior secured obligations, will be senior in right of payment to any existing and future subordinated indebtedness of the Company, pari passu in right of payment with all existing and future senior indebtedness of the Company, including its indebtedness under the Credit Agreement8, secured on a first-priority basis by the collateral owned by the Company (subject to permitted liens) on a pari passu basis as to the collateral owned by the Company with respect to borrowings under the Credit Agreement8 and any other future first lien obligations, structurally subordinated to all existing and future indebtedness, claims of holders of preferred stock and other liabilities of subsidiaries of the Company that do not guarantee the Notes, effectively senior to all existing and future unsecured indebtedness and other unsecured obligations of the Company to the extent of the value of the collateral owned by the Company, after giving effect to the intercreditor arrangements with the lenders under the Credit Agreement, effectively subordinated to any existing or future indebtedness of the Company that is secured by liens on assets that do not constitute a part of the collateral to the extent of the value of such assets, and unconditionally guaranteed by the Guarantors.
The Company may redeem some or all of the Notes prior to November 1, 2029, at a redemption price of 100% of the principal amount, plus accrued and un
Item 1.02
Item 1.02
Termination of a Material Definitive Agreement
On October 19, 2026, in connection with the entry into the Credit Agreement, the Company used a portion of the proceeds of the borrowings under the Credit Agreement and the offering of the Notes to repay in full all outstanding term loans and revolving loans, together with accrued and unpaid interest and fees, under its Seventh Amended and Restated Credit Agreement, dated as of March 24, 20239 (as amended by Amendment No. 1, dated as of June 6, 2025, and as otherwise amended prior to the date hereof, the "Existing Credit Agreement"), among the Company, the lenders party thereto and Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and the revolving commitments thereunder were terminated9. The Existing Credit Agreement provided for a $1.3 billion revolving credit facility and a $775 million term loan facility10, each scheduled to mature on March 24, 2028, subject to certain springing maturity conditions. Letters of credit outstanding under the Existing Credit Agreement were deemed issued under the Credit Agreement. The Company did not incur any early termination penalties in connection with the repayment of the Existing Credit Agreement.11
Item 2.03
Item 2.03
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Establishment Labs Holdings ESTA public float $975M, Jun 30, 2025
- NovoCure NVCR public float $995M, Jun 30, 2025
- Biolife Solutions BLFS public float $845M, Jun 30, 2025
- SI-BONE SIBN public float $800M, Jun 30, 2025
- Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
